Kerstin Noëlle Vokinger
Biographic Data
| ID | 8450192 |
|---|---|
| NAME | Kerstin Noëlle Vokinger |
| GIVEN NAMES | Kerstin Noëlle |
| FAMILY NAME | Vokinger |
| SIGNATURE | VOKINGER K N |
| AFFILIATIONS | University of Zurich |
| ORCID | 0000-0002-6997-7384 |
| VERIFIED | Yes |
| TOTAL WORKS | 7 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 7 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
New Medicare Payment Policy on Drug Shortages
This Viewpoint describes the Centers for Medicare & Medicaid Services’ new payment policy to establish and maintain buffer supplies of designated essential medicines and suggests additional reforms to improve this policy
Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland
The results of this cohort study suggest that, in contrast to Germany and Switzerland, prices of cancer drugs increased substantially post launch in the US. When developing solutions how drug prices can be decreased, launch as well as postlaunch prices require attention from policymakers
Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses
The findings of this cohort study demonstrate that drug prices were reduced substantially after patent expirations in high-income countries. Therefore, incorporating information on patent status and pricing dynamics in cost-effectiveness assessment analyses is necessary for producing accurate economic evaluations of new drugs
Investments in Research and Development for Supplemental Drug Indications—Implications for Drug Price Negotiations
This Viewpoint compares the research and development costs for a drug’s first indication with supplemental indications to demonstrate that the cost of approval for supplemental indications may be substantially lower
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
Importance The number of drugs approved through the accelerated approval or conditional marketing authorization pathways has increased with unclear evidence of their therapeutic value. Objectives To assess the therapeutic value of drug indications granted accelerated approval in the US or conditional marketing authorization in the European Union (EU) overall and for cancer indications. Design, Setting, and Participants This cohort study used the …
Negotiating Drug Prices in the US—Lessons From Europe
This Viewpoint describes European drug price negotiation practices and compares them with practices in the US
Accessibility of cancer drugs in Switzerland
No prominent works on this page.
Accessibility of cancer drugs in Switzerland
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
Importance The number of drugs approved through the accelerated approval or conditional marketing authorization pathways has increased with unclear evidence of their therapeutic value. Objectives To assess the therapeutic value of drug indications granted accelerated approval in the US or conditional marketing authorization in the European Union (EU) overall and for cancer indications. Design, Setting, and Participants This cohort study used the …
Negotiating Drug Prices in the US—Lessons From Europe
This Viewpoint describes European drug price negotiation practices and compares them with practices in the US
Investments in Research and Development for Supplemental Drug Indications—Implications for Drug Price Negotiations
This Viewpoint compares the research and development costs for a drug’s first indication with supplemental indications to demonstrate that the cost of approval for supplemental indications may be substantially lower
Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland
The results of this cohort study suggest that, in contrast to Germany and Switzerland, prices of cancer drugs increased substantially post launch in the US. When developing solutions how drug prices can be decreased, launch as well as postlaunch prices require attention from policymakers
Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses
The findings of this cohort study demonstrate that drug prices were reduced substantially after patent expirations in high-income countries. Therefore, incorporating information on patent status and pricing dynamics in cost-effectiveness assessment analyses is necessary for producing accurate economic evaluations of new drugs
New Medicare Payment Policy on Drug Shortages
This Viewpoint describes the Centers for Medicare & Medicaid Services’ new payment policy to establish and maintain buffer supplies of designated essential medicines and suggests additional reforms to improve this policy
Pharmaceutical Economics and Policy (7 works) · Health Systems, Economic Evaluations, Quality of Life (6 works) · Medicine (6 works) · Business (5 works) · Drug (5 works) · Drug prices (4 works) · Economic and Financial Impacts of Cancer (4 works) · Economics (4 works) · Pharmacology (4 works) · Public economics (4 works)